Search results for "INU"

showing 10 items of 5427 documents

Effects on Heat Stress of a Flame-Retardant Ensemble for Aluminum Smelters

2000

A common belief is that a flame-retardant clothing ensemble will increase the level of heat stress over ordinary cotton work clothes. This is supported by bench tests on fabrics that indicate higher insulation and vapor resistance values for flame-retardant clothing. This research compared a flame-retardant clothing ensemble for an aluminum smelter (Zirpo wool shirt and FR8 denim pants) with typical cotton work clothing. Four young men walked on a treadmill at two work levels inside a climatic chamber under controlled conditions of heat stress. During each test, heart rate, core temperature, and skin temperatures were continuously monitored and recorded every 5 min. After a physiological st…

AdultMaleWork (thermodynamics)Threshold limit valuebusiness.industryWet-bulb globe temperatureEnvironmental engineeringPublic Health Environmental and Occupational HealthHumidityHeat Stress DisordersAtmospheric sciencesClothingStress (mechanics)Protective ClothingInflection pointOccupational ExposureMetallurgyHumansEnvironmental scienceRelative humidityThreshold Limit ValuesbusinessAluminumFlame RetardantsAIHAJ
researchProduct

Marginal bone loss around implants placed in maxillary native bone or grafted sinuses: a retrospective cohort study

2013

Objectives To assess differences in marginal bone loss around implants placed in maxillary pristine bone and implants placed following maxillary sinus augmentation over a period of 3 years after functional loading. Material and methods Two cohorts of subjects (Group 1: Subjects who received sinus augmentation with simultaneous implant placement; Group 2: Subjects who underwent conventional implant placement in posterior maxillary pristine bone) were included in this retrospective study. Radiographic marginal bone loss was measured around one implant per patient on digitized panoramic radiographs that were obtained at the time of prosthesis delivery (baseline) and 12, 24, and 36 months later…

AdultMalealveolar bone lossbone graftingMaxillary sinusAdolescentRadiographymedicine.medical_treatmentAlveolar Bone LossDentistrySinus Floor AugmentationBone graftingProsthesisBone resorptionRisk Factorsdental implantsRadiography PanoramicMaxillaMedicineHumansPeriodontitisSinus (anatomy)AgedRetrospective StudiesOrthodonticsPeriodontitisDental Implantsbusiness.industryDental Implantation EndosseousSmokingMiddle Agedmedicine.diseasemedicine.anatomical_structureFemaleImplantOral Surgerymaxillary sinusbusinessbone resorption
researchProduct

Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients

2004

. Objectives.  To evaluate, in a group of nondiabetic essential hypertensive patients with normal renal function, the relationship between albumin excretion rate (AER) and carotid-femoral pulse wave velocity (PWV), as an index of aortic stiffness. Design.  Cross-sectional study. Setting.  Outpatient hypertension clinic. Subjects.  Seventy patients with mild-to-moderate essential hypertension, aged 42 ± 8 years, never pharmacologically treated. All subjects underwent routine laboratory tests, 24-h ambulatory blood pressure (BP) monitoring, measurement of carotid-femoral PWV, by means of a computerized method, and AER. Results.  Microalbuminuric patients (AER ≥ 20 μg min−1; n = 19), when comp…

AdultMalecardiovascular riskmedicine.medical_specialtyarterial hypertensionAmbulatory blood pressureSettore MED/09 - Medicina Internamicroalbuminuriapulse wave velocityDiastoleEssential hypertensionRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaHumansaortic stiffness;arterial hypertension;cardiovascular risk;microalbuminuria;pulse wave velocityRisk factorPulsePulse wave velocityAortaSettore MED/14 - NefrologiaProteinuriabusiness.industryaortic stiffneBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareElasticityFemoral ArteryEndocrinologyCarotid ArteriesCross-Sectional StudiesHypertensionCardiologyRegression AnalysisMicroalbuminuriaFemalemedicine.symptombusinessBody mass indexBlood Flow Velocity
researchProduct

Thyrotropin-releasing hormone has stimulatory effects on ventilation in humans

1991

Thyrotropin-releasing hormone (TRH) stimulates pituitary thyrotropin synthesis and release and also regulates autonomic nervous system functions by acting as a neuromodulator and neurotransmitter. In experimental animals a stimulation of ventilation by thyrotropin-releasing hormone was shown when applied at central nervous system sites that affect respiratory motor output. It was the goal of our study to investigate the respiratory properties of thyrotropin-releasing hormone on basal and stimulated (i.e. CO2-rebreathing) conditions following systemic thyrotropin-releasing hormone application in healthy humans. Thyrotropin-releasing hormone (200 micrograms, 400 micrograms intravenous) initia…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentRespiratory ratePhysiologyStatistics as TopicCentral nervous systemThyrotropin-releasing hormoneInternal medicinemedicineHumansRespiratory systemThyrotropin-Releasing Hormonebusiness.industryRespirationRespiratory Function TestsAutonomic nervous systemmedicine.anatomical_structureEndocrinologyBreathingFemalebusinessRespiratory minute volumeHormoneActa Physiologica Scandinavica
researchProduct

Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.

1997

This study was designed to assess patients with chronic hepatitis C (CHC) for the presence of thyroid autoimmunity and dysfunction, to evaluate the risk of thyroid disorders associated with interferon (IFN) therapy, and to survey the outcome of possible treatment-related thyroid injury. Out of 104 consecutive untreated patients (30 women and 74 men; mean age, 52.7 years), 8 (7.7%) were found seropositive for thyroid autoantibodies (ThyAb), whereas seropositivity in healthy controls was 1/98 (1.3%). The relative increase in risk of developing thyroid autoimmunity associated with CHC was 760% (95% Cl, 220–1300%). No patients had abnormalities of thyroid function tests, but on IFN treatment, 3…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismThyroid GlandThyrotropinInterferon alpha-2Thyroid function testsGastroenterologyIodide PeroxidaseThyroiditisAutoimmune DiseasesAutoimmune thyroiditisEndocrinologyInternal medicinemedicineHumansProspective StudiesAutoantibodiesAutoimmune diseasemedicine.diagnostic_testbusiness.industryThyroidInterferon-alphaMiddle Agedmedicine.diseaseHepatitis CThyroid DiseasesAnti-thyroid autoantibodiesRecombinant ProteinsDiscontinuationThyroxinemedicine.anatomical_structureImmunologyTriiodothyronineFemaleThyroid functionbusiness
researchProduct

Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives

2000

Previous evidence has demonstrated a relationship between growth factors and cardiovascular diseases. This study was aimed at evaluating levels of some endothelium-derived growth factors, and their relationship with microalbuminuria (MAU), in essential hypertension. Ninety-nine mild-moderate essential hypertensives (EH) and 25 healthy controls were studied. All patients underwent 24-h blood pressure monitoring, serum endothelin-1 (ET-1), basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF), and 24-h MAU assays. Later, EH were divided into two subsets consisting of microalbuminurics (MAU >11 microg/min) and nonmicroalbuminurics (MAU <11 microg/min). In microalbumin…

AdultMalemedicine.hormonemedicine.medical_specialtyPlatelet-derived growth factorBasic fibroblast growth factorBlood PressureEnzyme-Linked Immunosorbent AssayEssential hypertensionEndothelinschemistry.chemical_compoundInternal medicineInternal MedicinemedicineAlbuminuriaHumansPlatelet-Derived Growth FactorCreatinineProteinuriaEndothelin-1business.industryBlood Pressure Monitoring Ambulatorymedicine.diseaseEndocrinologyBlood pressurechemistrySpectrophotometryCreatinineHypertensionFemaleFibroblast Growth Factor 2MicroalbuminuriaEndothelium Vascularmedicine.symptombusinessBiomarkersAmerican Journal of Hypertension
researchProduct

Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.

2012

Background: Corticosteroids are effective in the treatment of Crohn's disease but some patients relapse during tapering or after discontinuation. We report data on efficacy and prognostic factors of response of adalimumab in steroid-dependent patients. Methods: In all, 110 steroid-dependent patients were treated with adalimumab (80/40 or 160/80 mg every other week followed by 40 mg every other week). Clinical remission was defined as steroid discontinuation without symptomatic recurrence and clinical response as the reduction or maintenance of the initial Crohn's Disease Activity Index (CDAI) value reducing steroid dosage but without its discontinuation at week 6 and at the end of follow-up…

AdultMalemedicine.medical_specialtyAdolescentAnti-Inflammatory AgentsAntibodies Monoclonal HumanizedInflammatory bowel diseaseYoung AdultCrohn DiseaseInternal medicinemedicineAdalimumabSecondary PreventionImmunology and AllergyHumansProspective StudiesYoung adultProspective cohort studyGlucocorticoidsAgedUnivariate analysisCrohn's diseasebusiness.industryRemission InductionGastroenterologyAdalimumabMiddle Agedmedicine.diseasePrognosisSurgeryDiscontinuationRegimenFemalebusinessmedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.

2019

Background An estimated 7% of patients with asthma have chronic rhinosinusitis with nasal polyps (CRSwNP), and more than 80% have at least some radiographic evidence of sinonasal inflammation. Aspirin sensitivity is strongly associated with elevated blood eosinophil levels and increased asthma severity. Intravenous (IV) reslizumab has been shown to improve asthma control in patients with nasal polyps. Objective These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity. Methods Patients aged 12-75 years with e…

AdultMalemedicine.medical_specialtyAdolescentComorbidityPlaceboAntibodies Monoclonal Humanized03 medical and health sciencesYoung Adult0302 clinical medicineNasal PolypsReslizumabMaintenance therapyInternal medicinemedicineImmunology and AllergyHumansNasal polyps030212 general & internal medicineAnti-Asthmatic AgentsPulmonary EosinophiliaSinusitisChildAsthmaAgedRhinitisAspirinbusiness.industryMinimal clinically important differenceAnti-Inflammatory Agents Non-SteroidalEosinophilMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsmedicine.anatomical_structureTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireChronic DiseaseFemaleSelf Reportbusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard…

2011

Abstract The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with Behçet’s disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and then…

AdultMalemedicine.medical_specialtyAdolescentCyclophosphamideImmunologyAzathioprineBehcet's diseaseRheumatologyPrednisoneInternal medicinemedicineHumansImmunology and AllergyAdverse effectAgedTumor Necrosis Factor-alphabusiness.industryBehcet SyndromeAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabSurgeryDiscontinuationBehçet’s disease - TNF alfa - InfliximabClinical trialTreatment OutcomeAntirheumatic AgentsFemalebusinessmedicine.drug
researchProduct

Clinical activity after fingolimod cessation: Disease reactivation or rebound?

2018

Background and purpose There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%…

AdultMalemedicine.medical_specialtyAdolescentDiseaseCohort StudiesMultiple sclerosisImmunosuppressive AgentYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrenceInternal medicineHumansMedicine030212 general & internal medicineFingolimod; Multiple sclerosis; Reactivation; Rebound; Neurology; Neurology (clinical)Natural courseReboundFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseReactivationMagnetic Resonance ImagingFingolimodDiscontinuationItalyWithholding TreatmentNeurologymultiple sclerosiCohortFemaleNeurology (clinical)Cohort StudiebusinessImmunosuppressive Agents030217 neurology & neurosurgeryHumanmedicine.drug
researchProduct